Stands on 1 first-party reading of the FDA and USDA FSIS recall lists, not reporting.
Recall issued for injectable products due to sterility concerns AI illustrationhow this picture was madeFDA and USDA FSIS have published eight separate Class II drug recalls for compounded injectable products manufactured by Carolina Infusion LLC of Ridgeland, South Carolina. All recall notices were posted on 10 September 2026.[1]
Recalled products include multiple strength formulations of semaglutide, tirzepatide, and combinations of each agent with cyanocobalamin. All products are supplied in single-use dosage syringes.
All eight notices identify the same deficiency: lack of assurance of sterility. Regulators linked the sterility concern to use of bacteriostatic water in product formulation, and to processing equipment used for the compounded items.
Dispensed volume for each product is calculated based on the specific patient prescription.
Proof1 source · 1 publisher · signed
What this stands on
FDA drug recall: TIRZEPATIDE/CYANOCOBALAMIN 76/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936 recalled by Carolina Infusion, LLC (Class II), for Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. (2026-09-10). · FDA and USDA FSIS, read by the Food and drug recalls instrument · the fact record↗
Read directly from the FDA and USDA FSIS recall lists, not from anyone's report of it.
